Tallón-Aguilar L, Serrano-Borrero I, López-Porras M, Sousa-Vaquero JM, León-Carrillo J

Language: Spanish
References: 11
Page: 320-323
PDF size: 377.62 Kb.

ABSTRACT

Background: Male breast cancer has a very low incidence (‹1%). It has traditionally been considered to have a poorer prognosis than breast cancer in females due to delayed diagnosis as a cause of decreased survival. Our goal is to analyze our series and to identify factors influencing survival.
Methods: We conducted a retrospective study from 1997–2008 (n = 32). Inclusion criteria were male gender and histological confirmation of breast cancer. We analyzed epidemiological data (age and personal and family history), tumors (size, grade of differentiation, histological type, location, TNM stage, receptors), therapeutic regimen (surgical technique, adjuvant therapy) and survival (relapse, followup, death).
Results: Male breast cancer represents 0.9% of all breast cancers treated in our center. The average age of our patients was 66.84 years. Only 9.3% demonstrated gynecomastia as a presenting complaint. Histologically, 90% were infiltrating ductal type; 59.25% were diagnosed in early stages (I–II) compared to 40.74% in stages III-IV. Aggressive surgical techniques are still performed, compared to conservative techniques (74.19% vs. 19.36%). With a median follow-up of 52.82 months, the mortality rate was 16%. Existence of distant metastasis has been the only statistically significant factor in survival.
Conclusions: The percentage of cases of male breast cancer is very low compared to breast cancer in females. Limited studies in the literature make gender-specific findings difficult. A low percentage of conservative surgical procedures are performed, even though this has increased considerably in recent years. The existence of distant metastasis was the main determinant of survival.

REFERENCES

1. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:20-26.

2. Smolin Y, Massie MJ. Male breast cancer: a review of the literature and a case report. Psychosomatics 2002;43:326-330.

3. Monteagudo B, Ginarte M, Labandeira J, Pereiro M Jr, de las Heras C, García- Rego JA, et al. Male breast carcinoma. Actas Dermosifiliogr 2006;97:75-76.

4. Chung HC, Koh EH, Roh JK, Min JS, Lee KS, Suh CO, et al. Male breast cancer – a 20-year review of 16 cases at Yonsei University. Yonsei Med J 1990;31:242-250.

5. Williams WL Jr, Powers M, Wagman LD. Cancer of the male breast: a review. J Natl Med Assoc 1996;88:439-443.

6. Park S, Kim JH, Koo J, Park BW, Lee KS. Clinicopathological characteristics of male breast cancer. Yonsei Med J 2008;49:978-986.

7. Meguerditchian AN, Falardeau M, Martin G. Male breast carcinoma. Can J Surg 2002;45:296-302.

8. Salinas-Martín MV, Carranza-Carranza A, Sánchez-Gallego F. Cáncer de mama en el varón. Características anatomoclínicas. Cir Esp 2008;83:94.

9. Davidson AT. A review of the treatment of cancer of the male breast with a case follow-up. J Natl Med Assoc 1987;79:879-880.

10. Cimmino VM, Degnim AC, Sabel MS, Diehl KM, Newman LA, Chang AE. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol 2004;86:74-77.

11. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol 2008;6:58-68.